Clinical Trials
32 trialsA Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
Vaccine Therapy in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
Ipilimumab and Local Radiation for Selected Solid Tumors
Stanford University
GEN602
Genzada Pharmaceuticals USA, Inc.
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
Provectus Pharmaceuticals
Safety Study of MGD009 in B7-H3-expressing Tumors
MacroGenics
A Study of ASN007 in Patients With Advanced Solid Tumors
Asana BioSciences
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Abramson Cancer Center at Penn Medicine
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
University of Wisconsin, Madison
rSIFN-01
Sichuan Huiyang Life Science and Technology Corporation
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Rutgers, The State University of New Jersey
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
City of Hope Medical Center
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Merck Sharp & Dohme LLC
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Calando Pharmaceuticals
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
Altor BioScience
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
BCX-1777 in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
National Institutes of Health Clinical Center (CC)
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
Rutgers, The State University of New Jersey
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center